Given the mechanism of action of NILK-2301 compared with other approved anti-cancer agents and the presumably non-overlapping toxicity profile, it is anticipated that NILK-2301 will combine favorably with other treatment modalities, e.g., immune checkpoint inhibitors [34], co-stimulatory agents like tumor-targeted 4-1BB agonists or CD28-BsAbs [60–62], or CD47-targeting BsAbs [63], in future clinical studies. Here, CD47 is linked to neoplasm.